Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Biogen

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV-based gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Recipient: Cevec

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 08, 2021

            Details:

            Under the terms of the agreement, CEVEC grants Biogen a non-exclusive license for CEVEC’s ELEVECTA® Technology. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nusinersen

            Therapeutic Area: Genetic Disease Product Name: Spinraza

            Highest Development Status: Phase IV Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2021

            Details:

            The RESPOND study aims to evaluate if Spinraza can benefit SMA patients who have experienced a ‘suboptimal’ response to Zolgensma (onasemnogene abeparvovec). It will be conducted at around 20 sites globally, with researchers aiming to enrol up to 60 children with SMA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VG801

            Therapeutic Area: Ophthalmology Product Name: VG801

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Recipient: ViGeneron

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 05, 2021

            Details:

            The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: BIIB037

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eisai Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2020

            Details:

            Aducanumab, an amyloid beta-targeting antibody, has been shown in clinical trials to remove amyloid beta in the brain and significantly slow clinical decline in patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease dementia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SAGE-217

            Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Sage Therapeutics

            Deal Size: $3,125.0 million Upfront Cash: $1,525.0 million

            Deal Type: Collaboration November 27, 2020

            Details:

            The deal would give Biogen rights to a treatment for multiple types of depression, called SAGE-217 or zuranolone, as well as a treatment for essential tremor and other neurological disorders, called SAGE-324.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ISD-017

            Therapeutic Area: Immunology Product Name: ISD-017

            Highest Development Status: Preclinical Product Type: Peptide

            Recipient: ISD Immunotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 23, 2020

            Details:

            ISD and Biogen will work together to develop ISD's lead compound, ISD 017, which is being developed to treat severe lupus - systemic lupus erythematosus (SLE).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ranibizumab

            Therapeutic Area: Ophthalmology Product Name: SB11

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: Samsung Bioepis

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 18, 2020

            Details:

            If approved, SB11 will add to the biosimilars portfolio developed by Samsung Bioepis and commercialized by Biogen, including three widely prescribed anti-TNF biosimilars in Europe; BENEPALI™, IMRALDI™ and FLIXABI™.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: BIIB037

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            Data from Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab's eventual approval, boosting chances that Biogen's drug could the market for Alzheimer's patients in the future.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BIIB059

            Therapeutic Area: Immunology Product Name: BIIB059

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 03, 2020

            Details:

            In Phase 2 LILAC study, BIIB059 (anti-BDCA2) demonstrated a statistically significant reduction in joint disease activity compared to placebo in systemic lupus erythematosus patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aducanumab

            Therapeutic Area: Neurology Product Name: BIIB037

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 30, 2020

            Details:

            Clinical data from patients with Mild Cognitive Impairment due to Alzheimer’s disease and mild Alzheimer’s disease demonstrate that treatment with aducanumab resulted in the removal of amyloid beta and better clinical outcomes.

            PharmaCompass